Analysts Set IQVIA Holdings Inc. (NYSE:IQV) PT at $241.50

Shares of IQVIA Holdings Inc. (NYSE:IQV) have received an average recommendation of “Moderate Buy” from the twenty-two brokerages that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $241.50.

A number of equities research analysts recently issued reports on IQV shares. UBS Group decreased their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Morgan Stanley boosted their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Finally, Citigroup lowered their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th.

Hedge Funds Weigh In On IQVIA

A number of institutional investors have recently modified their holdings of IQV. Smith Group Asset Management LLC bought a new position in IQVIA in the fourth quarter worth approximately $1,616,000. Nordea Investment Management AB grew its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. bought a new position in shares of IQVIA during the 4th quarter worth $941,000. Fifth Third Bancorp raised its holdings in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Finally, Graphene Investments SAS lifted its stake in IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock worth $2,948,000 after acquiring an additional 2,700 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 1.5 %

IQV opened at $145.40 on Friday. The company has a market capitalization of $25.64 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The firm has a 50-day simple moving average of $182.32 and a two-hundred day simple moving average of $199.38. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA has a 52 week low of $135.97 and a 52 week high of $252.88.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts forecast that IQVIA will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.